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A b s t r a c t
We evaluated analytic performances of an 
automated treponemal test and compared this test with 
the Venereal Disease Research Laboratory test (VDRL) 
and fluorescent treponemal antibody absorption test 
(FTA-ABS). Precision performance of the Architect 
Syphilis TP assay (TP; Abbott Japan, Tokyo, Japan) 
was assessed, and 150 serum samples were assayed 
with the TP before and after heat inactivation to 
estimate the effect of heat inactivation. A total of 616 
specimens were tested with the FTA-ABS and TP, and 
400 were examined with the VDRL. The TP showed 
good precision performance with total imprecision of 
less than a 10% coefficient of variation. An excellent 
linear relationship between results before and after 
heat inactivation was observed (R2 = 0.9961). The 
FTA-ABS and TP agreed well with a κ coefficient of 
0.981. The concordance rate between the FTA-ABS 
and TP was the highest (99.0%), followed by the rates 
between FTA-ABS and VDRL (85.0%) and between TP 
and VDRL (83.8%). The automated TP assay may be 
adequate for screening for syphilis in a large volume of 
samples and can be an alternative to FTA-ABS.
Syphilis is a disease caused by Treponema pallidum infec-
tion. An estimated 70,000 sexually transmitted infections with 
T pallidum occur each year in the United States,1 and, world-
wide, approximately 12 million new cases of syphilis occurred 
in 1997.2 Also in Korea, the number of newly infected patients 
reached about 1,500 in 2009 since the lowest number of 
134 was recorded in 2002.3 Because this disease has clini-
cal manifestations similar to those of nontreponemal disease, 
laboratory diagnostic tests with history taking and physical 
examination are mandatory for the diagnosis. Although there 
is no single definitive test, identification of T pallidum by 
dark-field microscopy or direct fluorescent antibody staining 
is considered the “gold standard” for the diagnosis. However, 
such methods require specimens obtained from moist lesions 
and need to be performed by an experienced laboratory tech-
nician.4,5 Polymerase chain reaction–based tests are fairly 
expensive compared with conventional laboratory tests,6-8 and 
real-time polymerase chain reaction provides limited sensitivi-
ties for secondary and latent syphilis.9,10 Thus, serologic tests 
are still widely used for syphilis diagnosis owing to reasonable 
costs and familiarity to practicing clinicians.
Serologic tests for the diagnosis of syphilis fall into 2 cat-
egories: nontreponemal tests and treponemal tests. Nontrepo-
nemal tests, which include the Venereal Disease Research 
Laboratory (VDRL) and the rapid plasma reagin tests, identify 
both IgG and IgM antilipoidal antibodies produced by the 
host in response to lipoidal materials released from damaged 
host cells and lipid from the cell surface of the T pallidum 
itself,4,5 whereas treponemal tests detect antibodies specific to 
T pallidum and include the fluorescent treponemal antibody 
absorption (FTA-ABS), T pallidum hemagglutination, and T 
pallidum particle agglutination.
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In some countries, including the United States and Korea, 
nontreponemal tests are used as a first-line test in screening for 
syphilis, and positive results of nontreponemal tests are con-
firmed by a treponemal test.4 However, this strategy may not 
properly diagnose cases of late latent syphilis and could delay 
the diagnosis while confirming with treponemal tests. In these 
respects, some European countries, such the United Kingdom 
and Germany, adopted treponemal tests as a screening test for 
syphilis.11 In addition, sensitivities of treponemal tests such as 
the FTA-ABS are known to be higher than those of nontrepo-
nemal tests.5 Hence, treponemal tests can be more useful in 
screening for syphilis.12,13 However, these conventional tests 
still require well-trained laboratory technicians to perform 
manual procedures such as heat inactivation and to interpret 
the results. For example, antigens need to be freshly prepared 
for everyday VDRL tests. Biologic false-positive results, espe-
cially in nontreponemal tests, are also problematic.12,14
Presently, some immunoassay reagents and autoana-
lyzers for the detection of antilipoidal antibody or T pal-
lidum–specific antibody (TP-specific Ab) are commercially 
available.15,16 Earlier reagents for TP-specific Ab mainly used 
turbidimetric methods, such as T pallidum particle agglutina-
tion, and then an automated chemiluminescent microparticle 
immunoassay was developed. In this study, we evaluated 
analytic performance of this assay and compared the results 
with those of other conventional tests for syphilis.
Materials and Methods
Architect Syphilis TP Assay
The Architect Syphilis TP (TP) assay (Abbott Japan, 
Tokyo, Japan) is a 2-step chemiluminescent microparticle 
immunoassay for the qualitative detection of antibody to T 
pallidum in serum or plasma using an Architect i System 
(Abbott Laboratories, Abbott Park, IL). During the assay, 
microparticles coated with recombinant TP antigens (TpN15, 
TpN17, and TpN47) bind to anti-TP antibodies presented by 
the specimen. After washing the specimen, mouse antihuman 
IgG-IgM conjugate labeled with a chemiluminescent mol-
ecule of acridinium is added, and the resultant chemilumines-
cent reaction is measured in relative light units (RLUs), which 
are directly related to the amount of TP-specific Ab in the 
specimen. The Architect analyzer calculates a ratio between 
the sample RLU and cutoff RLU, and samples with a ratio of 
more than 1.0 were considered positive.
VDRL Test
VDRL was tested using BD VDRL Antigen kits (Bec-
ton Dickinson, Sparks, MD) according to the manufacturer’s 
instructions. An antigen suspension was prepared before testing 
and used within 4 hours. All serum specimens were heated at 
56°C for 30 minutes before testing. When an undiluted sample 
was reactive for VDRL, semiquantitative tests were performed 
with a serial dilution of the sample to a 1:32 ratio. The results 
were interpreted using a microscope at ×100 magnification.
FTA-ABS Indirect Fluorescent Antibody Test
FTA-ABS tests were performed after samples were 
heated at 56°C for 30 minutes. Commercially available glass 
slides (Zeus Scientific, Raritan, NJ) on which T pallidum 
substrate had been fixed were used according to the manu-
facturer’s instructions. Every testing batch of patient samples 
was tested with negative and positive controls with 1+ to 
4+ reactivity. The slides were examined with a fluorescence 
microscope, and positive results were graded on a scale of 1+ 
to 4+ or recorded as minimally reactive. All minimally reac-
tive samples and those graded as 1+ were repeatedly tested.
Specimens
A total of 616 serum samples, which had been obtained 
for requested FTA-ABS tests by various departments includ-
ing general medicine and dermatology, were collected from 
people who were suspected of having syphilis or who took 
a medical examination at Severance Hospital of Yonsei Uni-
versity, Seoul, Korea, or Seoul National University Hospital, 
Seoul, Korea. The mean ± SD age of subjects was 48.8 ± 16.1 
years, and there were 313 males and 303 females, includ-
ing 2 pregnant women. All specimens were stored at –70°C 
after FTA-ABS tests were finished and were tested with TP. 
The VDRL was additionally done in 400 specimens, which 
were obtained from 203 males and 197 females. The medi-
cal records were reviewed if the results of the 3 tests did not 
agree. In addition, 108 serum samples with positive antinucle-
ar antibodies and nonreactive with the VDRL and FTA-ABS 
tests were assayed on the TP to evaluate possible interference 
on the TP by antinuclear antibodies. This study was approved 
by the institutional review board of Severance Hospital.
Precision Performance of the Syphilis TP Assay
Precision performance of the TP assay was assessed 
based on the guidelines in Clinical and Laboratory Standards 
Institute document EP15-A.17 The assay was performed in 
duplicate with positive and negative control samples and 
pooled sera with 2 levels twice a day for 5 days, and the result-
ing RLUs were analyzed.
Effect of Heat Inactivation on the TP Assay
A total of 150 serum samples were assayed on the TP 
assay twice before and after heat inactivation, and the resul-
tant RLUs were compared.
Statistical Analysis
All statistical analyses were performed by using the 
Analyse-it Method Evaluation edition software, version 2.22 
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(Analyse-it Software, Leeds, England). A paired t test and 
linear regression analysis were carried out to evaluate the 
effect of heat inactivation on the TP assay. The κ coefficients 
were calculated to estimate the agreement of the results for 
the VDRL, FTA-ABS, and TP assays. Multiple pairwise 
comparison of the TP RLUs according to the groups classified 
by the results of VDRL or FTA-ABS tests were conducted 
using the Kruskal-Wallis test with Bonferroni correction to 
compensate for an α statistical error. P values less than .05 
were considered statistically significant.
Results
Precision of the TP Assay
The precision performance of the TP assay for samples 
with 4 concentrations (positive control, negative control, 
pooled serum 1, and pooled serum 2) are summarized in 
❚Table 1❚. The coefficient of variation (CV) for within-run 
imprecision ranged from 2.0% to 5.9%, and the CV for total 
imprecision was between 2.4% and 8.2%.
Effect of Heat Inactivation on the TP Assay
The mean ± SD RLUs for the TP assay were 8.37 ± 10.33 
before heat inactivation and 8.19 ± 9.96 after heat inactivation 
(n = 150), and there were small differences between the RLUs 
(mean ± SD difference, 0.18 ± 0.74; P = .0033). On the other 
hand, the results were well correlated with each other in linear 
regression analysis (R2 = 0.9961; P < .0001), and the follow-
ing equation was established: y = 0.9618x + 0.1399, where 
x represents RLUs before heat inactivation and y represents 
RLUs after heat inactivation.
Comparison Among VDRL, FTA-ABS, and TP Assays
The FTA-ABS and TP assays agreed better, with a κ of 
0.981, than the VDRL and FTA-ABS tests (κ = 0.700) and the 
VDRL and TP assays (κ = 0.675) ❚Table 2❚ and ❚Table 3❚. The 
❚Table 1❚
Precision Performance of the Architect TP Assay
   Coefficient of Variation (%) 
Sample Mean RLUs Repeatability Between-Run Between-Day Total
Positive control 2.36 5.90 0.00 4.50 7.40
Negative control 0.22 4.80 6.40 2.00 8.20
Pooled serum 1 25.31 2.00 1.40 0.00 2.40
Pooled serum 2 0.89 3.20 2.50 4.00 5.70
RLUs, relative light units.
❚Table 2❚
Comparison of VDRL, FTA-ABS, and Architect TP Results
 VDRL
    Concordance
Comparative Test Reactive Nonreactive Total Rate (%) κ (95% CI) P
FTA-ABS      
   Reactive 155 15 170   
   Nonreactive 45 185 230   
   Total 200 200 400 85.0 0.700 (0.631-0.769) <.0001
Architect TP      
   Positive 152 17 169   
   Negative 48 183 231   
   Total 200 200 400 83.8 0.675 (0.604-0.746) <.0001
CI, confidence interval; FTA-ABS, fluorescent treponemal antibody absorption test; VDRL, Venereal Disease Research Laboratory test.
❚Table 3❚
Comparison of the Results Between the FTA-ABS and Architect TP
 FTA-ABS
    Concordance
Architect TP Reactive Nonreactive Total Rate (%) κ (95% CI) P
Positive 306 3 309   
Negative 3 304 307   
Total 309 307 616 99.0 0.981 (0.965-0.996) <.0001
CI, confidence interval; FTA-ABS, fluorescent treponemal antibody absorption test.
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reactivity group were as follows: 0.20 in the nonreactive 
group (n = 252), 4.11 in the minimally reactive group (n = 34), 
9.43 in the 1+ reactive group (n = 42), 10.87 in the 2+ reactive 
group (n = 139), 18.56 in the 3+ reactive group (n = 42), and 
28.28 in the 4+ reactive group (n = 7).
Specimens With Antinuclear Antibodies as Assay-
Interfering Substances
A total of 108 samples with various intensities of anti-
nuclear antibody from 1:40 to higher than 1:160 were tested 
in the TP assay. All specimens were negative for TP.
Discussion
In this study, we evaluated the analytic performance of 
an automated treponemal test, the Architect TP assay, and 
compared the results with those of other conventional tests. 
The TP assay showed good precision performance with a 
total imprecision of less than 10% CV and high agreement 
with conventional tests for syphilis, especially almost con-
cordant results with the FTA-ABS. The correlation between 
the TP and VDRL tests was slightly low, which is similar to 
previous reports.6,12,15,18
concordance rate between the results of the FTA-ABS and 
VDRL tests was 85.0%, and between the TP and VDRL tests, 
it was 83.8%. The results between the TP and FTA-ABS tests 
showed the highest concordance rate, 99.0%.
The RLUs for the TP assay were significantly lower in 
VDRL-nonreactive specimens than in all other VDRL-reactive 
groups (P < .0001) ❚Figure 1A❚. There were also significant 
differences in the TP RLUs between the VDRL 1:1 weakly 
reactive and 1:2 reactive groups (P = .0031), between the 
VDRL 1:1 weakly reactive and more than 1:8 reactive groups 
(P = .0011), and between the VDRL 1:1 reactive and more 
than 1:8 reactive groups (P = .0083). Otherwise, there was no 
difference in RLUs according to VDRL reactivity. The median 
TP RLU was 0.19 for the VDRL-nonreactive group (n = 200), 
7.49 for the 1:1 weakly reactive group (n = 107), 7.92 for the 
1:1 reactive group (n = 58), 21.67 for the 1:2 reactive group (n 
= 22), 20.89 for the 1:4 reactive group (n = 6), and 28.02 for 
the group designated more than 1:8 reactive (n = 7).
The RLUs of the TP assay were significantly different 
between most of the groups divided by FTA-ABS reactivity 
(overall, P < .0001) except between the FTA-ABS 1+ and 2+ 
(P = .5655) and between the FTA-ABS 3+ and 4+ groups (P = 
.7853) ❚Figure 1B❚. The median TP RLUs for each FTA-ABS 
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❚Figure 1❚ Architect TP relative light units (RLUs) according to reactivity of the fluorescent treponemal antibody absorption (FTA-
ABS) and Venereal Disease Research Laboratory (VDRL) tests. A, The RLUs were lower in the VDRL nonreactive group than in 
all other VDRL reactive groups. There were also significant differences in TP RLUs between VDRL 1:1 weakly reactive and 1:2 
reactive groups, between VDRL 1:1 weakly reactive and more than 1:8 reactive groups, and between VDRL 1:1 reactive and 
more than 1:8 reactive groups. B, The RLUs of the TP were different between most of the groups by FTA-ABS reactivity except 
between the FTA-ABS 1+ and 2+ and between the FTA-ABS 3+ and 4+ groups. Upper and lower ends of boxes indicate upper and 
lower quartiles, respectively; inner lines, median values; whiskers, maximum and minimum values; and circles, individual values.
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In addition, we evaluated effects of the heat inactivation 
process on TP assay results to identify whether heat-inactivat-
ed samples can be reliably tested on the TP assay. Because the 
FTA-ABS and VDRL tests are performed after heat inactiva-
tion, it is convenient to confirm the results of the VDRL and 
FTA-ABS tests with the TP assay using the samples after the 
former 2 tests are finished. As a result, the TP RLUs were 
slightly lower in heat-inactivated samples, but there was a 
linear relationship between the results obtained before and 
after heat inactivation, and the difference between the results 
was negligible. Therefore, heat-inactivated samples would be 
reliably assayed by the TP, although this is not recommended 
by the manufacturer.
In our data, there were some discrepancies in the VDRL, 
FTA-ABS, and TP results, and most discrepancies seemed to 
be caused by false-positive results in the VDRL test. A total of 
45 specimens with VDRL-reactive and FTA-ABS–nonreac-
tive results might have been caused by false positivity in the 
VDRL, which was assumed after reviewing patients’ records. 
There were 48 samples that were reactive with the VDRL and 
negative with the TP assay, and 45 of them were the ones that 
were positive with the VDRL and negative with the FTA-
ABS test. In the other 3 samples, the VDRL test results were 
thought to be false-positive because the patients did not have 
any evidence of syphilis infection. The mean TP RLU value 
for 48 VDRL-reactive and TP assay–negative specimens was 
0.27 (95% confidence interval, 0.06-0.93). The reasons for 
false positivity in the VDRL results corresponded with well-
known causes such as systemic lupus erythematosus, malig-
nancies, and hepatitis. Of the 2 pregnant women, 1 also had a 
false-positive result on the VDRL.
Meanwhile, 15 VDRL-nonreactive and FTA-ABS–reac-
tive specimens were obtained from patients already treated or 
with late latent syphilis, including the other pregnant woman. 
Additional 2 specimens with nonreactive VDRL and positive 
TP assay results might have resulted from the false-positive 
TP assay. The RLUs of the TP assay in these 2 cases were 
slightly higher than the cutoff (1.21 and 1.07). In addition, 
3 FTA-ABS–nonreactive and TP assay–positive specimens 
were supposed to be false-positive by TP, whereas another 3 
specimens with FTA-ABS–reactive and TP-negative results 
were presumed to be false-positive in the FTA-ABS test. 
Among the latter 3 cases, 2 samples were minimally reactive 
in the FTA-ABS test, and the patients had systemic lupus ery-
thematosus or hepatitis. Another patient had FTA-ABS reac-
tivity of 2+, but there was no clinical reason for the reactivity.
The VDRL test is useful for monitoring syphilis disease 
activity and treatment response.4,5,8,14 However, the sensitiv-
ity of the VDRL test is lower than that of treponemal tests 
such as the FTA-ABS, especially in primary and late latent 
syphilis.4,5,14 In our study, all VDRL-nonreactive and FTA-
ABS– or TP assay–positive samples were also obtained from 
already treated patients or patients with late latent syphilis. 
Assuming the diagnoses in patients’ medical records are cor-
rect, the sensitivity of the VDRL was 76%, which is similar 
to that in other studies.5,6,14,15,19 In this respect, there are pos-
sibilities for a wrong or delayed diagnosis when the VDRL 
test is used to screen for syphilis. Therefore, nontreponemal 
tests are appropriate for monitoring, and treponemal tests 
are suitable for screening and diagnosing syphilis. However, 
the procedure for FTA-ABS is complicated, and results may 
vary according to the person who interprets the fluorescent 
microscopic images. In this sense, the fully automated Archi-
tect TP assay, which does not involve complicated sample 
preparation process, has an advantage over the FTA-ABS test. 
In our study, TP assay results were highly concordant with 
FTA-ABS results (κ = 0.981). Some countries adopt different 
strategies for screening and confirming syphilis infections as 
stated earlier, and these strategies would be standardized.
In addition, cerebrospinal fluid (CSF) is generally 
screened by the FTA-ABS test for the diagnosis of neuro-
syphilis, and the VDRL can be performed as a confirmatory 
test15,20 because the FTA-ABS has high sensitivity and the 
VDRL has high specificity for the detection of neurosyphilis 
in CSF samples. We experimentally tested 44 CSF speci-
mens to evaluate the usefulness of the Architect TP for the 
diagnosis of neurosyphilis. However, results for 30 samples 
could not be obtained owing to a technical problem. Because 
the antibody quantity in CSF is usually low, the antigen 
quantity in the TP reagent kit may need to be optimized 
before applying it to CSF specimens, and further studies on 
the usefulness of the TP assay for the diagnosis of neuro-
syphilis would be necessary.
The Architect TP assay showed good precision and cor-
relation with conventional syphilis tests, especially the FTA-
ABS, which is known as the most sensitive treponemal test 
for syphilis. This automated TP assay is considered adequate 
for screening for syphilis in a large volume of samples owing 
to its convenience, and it can be an alternative to FTA-ABS.
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